2024 Q3 Form 10-Q Financial Statement
#000135657624000051 Filed on August 06, 2024
Income Statement
Concept | 2024 Q3 | 2024 Q2 |
---|---|---|
Revenue | $175.7M | $168.3M |
YoY Change | 14.17% | 24.17% |
Cost Of Revenue | $17.58M | $17.92M |
YoY Change | -10.3% | -15.05% |
Gross Profit | $158.1M | $150.4M |
YoY Change | 17.74% | 31.39% |
Gross Profit Margin | 89.99% | 89.36% |
Selling, General & Admin | $69.75M | $85.90M |
YoY Change | -15.66% | -1.01% |
% of Gross Profit | 44.12% | 57.11% |
Research & Development | $29.04M | $26.18M |
YoY Change | 28.17% | 7.4% |
% of Gross Profit | 18.36% | 17.41% |
Depreciation & Amortization | $20.10M | $20.72M |
YoY Change | -8.21% | -0.03% |
% of Gross Profit | 12.71% | 13.77% |
Operating Expenses | $98.79M | $112.1M |
YoY Change | -6.23% | 0.83% |
Operating Profit | $40.85M | $22.57M |
YoY Change | 401.9% | -228.33% |
Interest Expense | $4.098M | $3.733M |
YoY Change | 310.22% | |
% of Operating Profit | 10.03% | 16.54% |
Other Income/Expense, Net | $4.098M | $3.733M |
YoY Change | 134.04% | 711.52% |
Pretax Income | $44.94M | $26.30M |
YoY Change | 354.47% | -253.57% |
Income Tax | $6.400M | $6.400M |
% Of Pretax Income | 14.24% | 24.33% |
Net Earnings | $38.50M | $19.92M |
YoY Change | -340.97% | -2496.63% |
Net Earnings / Revenue | 21.91% | 11.83% |
Basic Earnings Per Share | $0.70 | $0.36 |
Diluted Earnings Per Share | $0.69 | $0.36 |
COMMON SHARES | ||
Basic Shares Outstanding | 55.11M shares | 54.97M shares |
Diluted Shares Outstanding | 56.02M shares | 55.72M shares |
Balance Sheet
Concept | 2024 Q3 | 2024 Q2 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $403.2M | $347.2M |
YoY Change | 101.4% | 128.93% |
Cash & Equivalents | $31.67M | $52.09M |
Short-Term Investments | $371.5M | $295.1M |
Other Short-Term Assets | $27.40M | $23.17M |
YoY Change | 14.66% | -48.25% |
Inventory | $63.98M | $68.16M |
Prepaid Expenses | ||
Receivables | $145.4M | $152.5M |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $640.0M | $591.0M |
YoY Change | 42.43% | 39.54% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $11.88M | $12.27M |
YoY Change | -13.24% | -13.48% |
Goodwill | $117.0M | $117.0M |
YoY Change | 0.0% | 0.0% |
Intangibles | $540.2M | $559.6M |
YoY Change | -15.75% | -15.51% |
Long-Term Investments | $0.00 | $0.00 |
YoY Change | -100.0% | -100.0% |
Other Assets | $33.65M | $35.89M |
YoY Change | -13.33% | -6.75% |
Total Long-Term Assets | $702.7M | $724.8M |
YoY Change | -15.93% | -16.64% |
TOTAL ASSETS | ||
Total Short-Term Assets | $640.0M | $591.0M |
Total Long-Term Assets | $702.7M | $724.8M |
Total Assets | $1.343B | $1.316B |
YoY Change | 4.48% | 1.76% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $6.392M | $4.628M |
YoY Change | 88.61% | 5.18% |
Accrued Expenses | $75.80M | $82.61M |
YoY Change | -3.4% | -0.52% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $291.5M | $308.7M |
YoY Change | 1.38% | 22.2% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Other Long-Term Liabilities | $7.350M | $7.288M |
YoY Change | -14.5% | -16.56% |
Total Long-Term Liabilities | $7.350M | $7.288M |
YoY Change | -14.5% | -16.56% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $291.5M | $308.7M |
Total Long-Term Liabilities | $7.350M | $7.288M |
Total Liabilities | $335.6M | $358.4M |
YoY Change | -10.03% | -3.97% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | $541.1M | $502.6M |
YoY Change | 12.4% | 1.05% |
Common Stock | $55.00K | $55.00K |
YoY Change | 0.0% | 0.0% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $1.007B | $957.5M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $1.343B | $1.316B |
YoY Change | 4.48% | 1.76% |
Cashflow Statement
Concept | 2024 Q3 | 2024 Q2 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | $38.50M | $19.92M |
YoY Change | -340.97% | -2496.63% |
Depreciation, Depletion And Amortization | $20.10M | $20.72M |
YoY Change | -8.21% | -0.03% |
Cash From Operating Activities | $53.52M | $35.62M |
YoY Change | 49.5% | -288.75% |
INVESTING ACTIVITIES | ||
Capital Expenditures | $200.0K | $64.00K |
YoY Change | 0.0% | -59.75% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | -$76.81M | -$48.53M |
YoY Change | -320.72% | -180.27% |
Cash From Investing Activities | -$77.01M | -$48.59M |
YoY Change | -322.58% | -180.59% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 3.075M | 1.658M |
YoY Change | -1125.0% | -100.35% |
NET CHANGE | ||
Cash From Operating Activities | 53.52M | 35.62M |
Cash From Investing Activities | -77.01M | -48.59M |
Cash From Financing Activities | 3.075M | 1.658M |
Net Change In Cash | -20.42M | -11.31M |
YoY Change | -129.12% | -97.41% |
FREE CASH FLOW | ||
Cash From Operating Activities | $53.52M | $35.62M |
Capital Expenditures | $200.0K | $64.00K |
Free Cash Flow | $53.32M | $35.56M |
YoY Change | 49.78% | -286.83% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2024Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
55046049 | shares |
us-gaap |
Net Income Loss
NetIncomeLoss
|
16117000 | usd | |
CY2024Q2 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent | |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent | |
CY2024Q2 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent | |
CY2023Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent | |
CY2024Q2 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent | |
CY2024Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
55046049 | shares |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
886204000 | usd |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6306000 | usd |
CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
1811000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
16948000 | usd |
CY2023Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
881000 | usd |
CY2023Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
1947000 | usd |
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-831000 | usd |
CY2023Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
554000 | usd |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
919908000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
20040000 | usd | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
41467000 | usd | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
41326000 | usd | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
0 | usd | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
532000 | usd | |
us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-1531000 | usd | |
us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
917000 | usd | |
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-5450000 | usd | |
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-857000 | usd | |
us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-6623000 | usd | |
us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-8427000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12449000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12394000 | usd | |
us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-13597000 | usd | |
us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-5989000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
8339000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-26364000 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-8015000 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
5830000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
6789000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
28544000 | usd | |
supn |
Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
|
20845000 | usd | |
supn |
Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
|
-2839000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-2770000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-29932000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
74025000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
30252000 | usd | |
us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
317680000 | usd | |
us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
0 | usd | |
us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
217774000 | usd | |
us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
300513000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
312000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
437000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-100218000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
300076000 | usd | |
us-gaap |
Proceeds From Short Term Debt
ProceedsFromShortTermDebt
|
0 | usd | |
us-gaap |
Proceeds From Short Term Debt
ProceedsFromShortTermDebt
|
93000000 | usd | |
us-gaap |
Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
|
0 | usd | |
us-gaap |
Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
|
93000000 | usd | |
us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
0 | usd | |
us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
402500000 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4569000 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4778000 | usd | |
us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
1341000 | usd | |
us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
1020000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3228000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-398742000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-22965000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-68414000 | usd | |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
75054000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93120000 | usd |
CY2024Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
52089000 | usd |
CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
24706000 | usd |
us-gaap |
Interest Paid Net
InterestPaidNet
|
0 | usd | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
1946000 | usd | |
us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
20762000 | usd | |
us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
20434000 | usd | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
8138000 | usd | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
8709000 | usd | |
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
3525000 | usd | |
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
3938000 | usd | |
us-gaap |
Nature Of Operations
NatureOfOperations
|
Business Organization<div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (the Company, see Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has seven commercial products that it markets: Qelbree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GOCOVRI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Oxtellar XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trokendi XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, APOKYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XADAGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and MYOBLOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("OFF" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Company submitted to the U.S. Food and Drug Administration (FDA) a notification of discontinuance to withdraw Osmolex ER from distribution. Distribution of Osmolex ER ceased on April 1, 2024.</span></div> | ||
supn |
Number Of Commercial Products
NumberOfCommercialProducts
|
7 | product | |
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment | |
us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior year amount related to the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee taxes paid related to net share settlement of equity awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of cash flows has been reclassified to conform to current year presentation. The reclassification did not affect the other condensed consolidated financial statements.</span></div> | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div> | ||
CY2024Q2 | us-gaap |
Advertising Expense
AdvertisingExpense
|
23500000 | usd |
us-gaap |
Advertising Expense
AdvertisingExpense
|
47900000 | usd | |
CY2023Q2 | us-gaap |
Advertising Expense
AdvertisingExpense
|
25900000 | usd |
us-gaap |
Advertising Expense
AdvertisingExpense
|
51800000 | usd | |
CY2024Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
168325000 | usd |
CY2023Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
135563000 | usd |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
311969000 | usd | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
289327000 | usd | |
CY2023Q2 | supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
1700000 | usd |
supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
4000000.0 | usd | |
CY2024Q2 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent
|
295528000 | usd |
CY2023Q4 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent
|
197153000 | usd |
CY2024Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1000 | usd |
CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
5000 | usd |
CY2024Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
431000 | usd |
CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
721000 | usd |
CY2024Q2 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
295098000 | usd |
CY2023Q4 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
196437000 | usd |
CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
295098000 | usd |
us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded
|
0 | usd | |
CY2024Q2 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
47303000 | usd |
CY2023Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
52070000 | usd |
CY2024Q2 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
697000 | usd |
CY2023Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
1380000 | usd |
CY2024Q2 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
48000000 | usd |
CY2023Q4 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
53450000 | usd |
CY2023Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
53450000 | usd |
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
5450000 | usd | |
CY2024Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
48000000 | usd |
CY2022Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
54967000 | usd |
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
857000 | usd | |
CY2023Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
54110000 | usd |
CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
|
P6Y4M9D | |
CY2024Q2 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
829131000 | usd |
CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
269487000 | usd |
CY2024Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
559644000 | usd |
CY2023Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
829131000 | usd |
CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
229242000 | usd |
CY2023Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
599889000 | usd |
CY2024Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
20100000 | usd |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
40200000 | usd | |
CY2023Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
20100000 | usd |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
40100000 | usd | |
CY2024Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6552000 | usd |
CY2023Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6088000 | usd |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
12449000 | usd | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
12394000 | usd | |
CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
19916000 | usd |
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-831000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
20040000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
16117000 | usd | |
CY2024Q2 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
0 | usd |
CY2023Q2 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
0 | usd |
us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
0 | usd | |
us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
892000 | usd | |
CY2024Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
19916000 | usd |
CY2023Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-831000 | usd |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
20040000 | usd | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
17009000 | usd | |
CY2024Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
54978781 | shares |
CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
54502993 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
54890265 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
54442463 | shares | |
CY2024Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
745502 | shares |
CY2023Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
0 | shares |
us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
785209 | shares | |
us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1181983 | shares | |
CY2024Q2 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares |
CY2023Q2 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares |
us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares | |
us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
3410708 | shares | |
CY2024Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
55724283 | shares |
CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54502993 | shares |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
55675474 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
59035154 | shares | |
CY2024Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.36 | |
CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.02 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.37 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.30 | ||
CY2024Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.36 | |
CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.02 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.36 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.29 | ||
CY2024Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
6386000 | usd |
CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-16296000 | usd |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
6505000 | usd | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-24227000 | usd | |
CY2024Q2 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.243 | |
CY2023Q2 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.951 | |
us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.245 | ||
us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
2.987 | ||
CY2024Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
6400000 | usd |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
6500000 | usd | |
CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-16300000 | usd |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-24200000 | usd | |
CY2024Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
27766000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
28994000 | usd |
CY2024Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
27766000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
28994000 | usd |
CY2024Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
9683000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
8331000 | usd |
CY2024Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
30294000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
33196000 | usd |
CY2024Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
39977000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
41527000 | usd |
CY2024Q2 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
15899000 | usd |
CY2023Q4 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
16274000 | usd |
CY2024Q2 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
23590000 | usd |
CY2023Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
31212000 | usd |
CY2024Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
28666000 | usd |
CY2023Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
29922000 | usd |
CY2024Q2 | us-gaap |
Inventory Net
InventoryNet
|
68155000 | usd |
CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
77408000 | usd |
CY2024Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
28901000 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
28935000 | usd |
CY2024Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
16627000 | usd |
CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
15405000 | usd |
CY2024Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
12274000 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
13530000 | usd |
CY2024Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
600000 | usd |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1200000 | usd | |
CY2023Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
600000 | usd |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1300000 | usd | |
CY2024Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4628000 | usd |
CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1964000 | usd |
CY2024Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
17039000 | usd |
CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
20722000 | usd |
CY2024Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
16444000 | usd |
CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
11666000 | usd |
CY2024Q2 | supn |
Accrued Manufacturing Expenses
AccruedManufacturingExpenses
|
8745000 | usd |
CY2023Q4 | supn |
Accrued Manufacturing Expenses
AccruedManufacturingExpenses
|
11652000 | usd |
CY2024Q2 | supn |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
9847000 | usd |
CY2023Q4 | supn |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
10530000 | usd |
CY2024Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
9683000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
8331000 | usd |
CY2024Q2 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
6861000 | usd |
CY2023Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
7918000 | usd |
CY2024Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
9364000 | usd |
CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
6786000 | usd |
CY2024Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
82611000 | usd |
CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
79569000 | usd |
CY2024Q2 | supn |
Accrued Rebates
AccruedRebates
|
116582000 | usd |
CY2023Q4 | supn |
Accrued Rebates
AccruedRebates
|
96984000 | usd |
CY2024Q2 | supn |
Accrued Product Returns
AccruedProductReturns
|
58537000 | usd |
CY2023Q4 | supn |
Accrued Product Returns
AccruedProductReturns
|
57290000 | usd |
CY2024Q2 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
175119000 | usd |
CY2023Q4 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
154274000 | usd |
CY2024Q2 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
0 | usd |
CY2023Q2 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
665000 | usd |
us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
0 | usd | |
us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
1321000 | usd | |
CY2024Q2 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
0 | usd |
CY2023Q2 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
245000 | usd |
us-gaap |
Interest Expense Other
InterestExpenseOther
|
0 | usd | |
us-gaap |
Interest Expense Other
InterestExpenseOther
|
562000 | usd | |
CY2024Q2 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
0 | usd |
CY2023Q2 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
0 | usd |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
0 | usd | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
532000 | usd | |
CY2024Q2 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
0 | usd |
CY2023Q2 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
910000 | usd |
us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
0 | usd | |
us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
2415000 | usd | |
CY2024Q2 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
CY2024Q2 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
CY2024Q2 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
CY2024Q2 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |